Characterization of the Role of Neurexin-1 in MPTP Induced Parkinsonism in Mice Model.

Abstract

The second-most prevalent neurological disorder in the world, Parkinson's disease (PD) affected roughly 6 million people as of 2016. The death and loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) is the primary pathogenic characteristic of PD. Motor abnormalities like limb stiffness, tremors, and bradykinesia are the major symptoms of PD. Parkinson's disease remains an unsolved clinical problem, as currently, authorized PD therapies offer relatively modest therapeutic benefits. In this study, mice models are utilized for PD induction by MPTP neurotoxin for functional characterization of proteomic factor Neurexin 1. The effect of co-administering clozapine drugs in MPTP mice models was analyzed through histological analyses, behavioural evaluations, and RT-PCR. Results showed that mice treated with clozapine had considerably upregulated the expression of NRXN-1 in the brain than mice treated with MPTP. These findings provide interesting directions for future approaches in establishing MPTP-induced neuronal injury and shed light on the possible therapeutic implications of NRXN1 in reducing neurodegeneration in Parkinson's disease along with studying the coherent expression of all three Neurexin genes.